Overview

Clinical Trial on the Prevention of Thrombocytopenia After First-line Chemotherapy

Status:
Terminated
Trial end date:
2016-08-01
Target enrollment:
Participant gender:
Summary
To assess the efficacy and safety of administration of rhTPO at different time in the treatment of thrombocytopenia caused by first-line GC/GP regimen for non small cell lung cancer (NSCLC)
Phase:
Phase 2/Phase 3
Details
Lead Sponsor:
Chinese Society of Lung Cancer